Why HIMS Abandoned Compounded Semaglutide

The $33M Decision: Why HIMS Walked Away

In March 2026, Hims & Hers made a striking business decision: voluntarily discontinue their compounded semaglutide product line. On paper, this made no sense. Compounded semaglutide represented their highest-margin offering—$79–99 per month with 75–80% gross margins. Yet they absorbed a $33 million write-down and walked away.

The reason wasn't revenue pressure or competition. It was regulatory clarity.

The Compounding Legal Gray Zone

Compounded semaglutide existed in a liminal space. The FDA has authority to regulate pharmacy compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. This section permits licensed pharmacies to compound medications when an FDA-approved equivalent is unavailable—or when a patient has a documented medical need for a customized formulation.

Semaglutide had approved formulations (Ozempic, Wegovy, Mounjaro alternatives). Yet for years, compounders argued they could legally produce semaglutide because:

• Approved versions faced intermittent supply constraints
• Patient demand exceeded supply
• Compounded versions cost 70–80% less than brand pharmaceutical semaglutide
• The regulatory language was vague enough to permit interpretation

This ambiguity created opportunity. Telehealth platforms and compounding pharmacies built entire business models on this gray zone.

What Changed in 2026

The FDA issued formal guidance clarifying that compounding semaglutide no longer qualified under the 503A exemption because:

1. Approved supply exists: Novo Nordisk, Eli Lilly (tirzepatide), and other manufacturers maintained adequate supply chains
2. Compounding is not "medically necessary": Absence of customization need means the exemption does not apply
3. Outsourcing Facilities (503B) are not the same as pharmacies (503A): Only licensed 503A pharmacies can compound for individual patients; commercial-scale compounding requires FDA approval

The distinction matters. A telehealth patient receiving compounded semaglutide from a pharmacy was technically within a legal framework that was always fragile. Once the FDA clarified that this was no longer permitted, continued distribution became a regulatory liability.

The Broader Peptide and Hormone Implications

This precedent extends beyond semaglutide. Similar pressure is building on compounded versions of:

• Tirzepatide (non-approved compounded formulations)
• BPC-157 and other peptides (no approved pharmaceutical equivalent; different regulatory pathway)
• Testosterone, estrogen, and DHT precursors (approved versions exist; compounding justification weakens)
• SARMS and selective androgen receptor modulators (no approved pharmaceutical version; gray zone remains)

The key principle: if an FDA-approved pharmaceutical-grade alternative exists, compounding loses its legal shelter. If no approved alternative exists, compounding may remain permissible but faces closer scrutiny.

What This Means for Peptide and Hormone Users

If you've been using compounded peptides or hormones:

Assess your baseline labs now. Before any regulatory action forces a transition, obtain comprehensive baseline testing:

• IGF-1, IGFBP-3, and GH axis markers (if using growth hormone secretagogues)
• Total and free testosterone, SHBG, estradiol, DHT (if using androgens)
• TSH, free T3, free T4 (if using thyroid support)
• DHEA-S, cortisol AM/PM (if using adaptogenic peptides)
• Fasting glucose, HbA1c, lipid panel

Verify pharmaceutical-grade sourcing. If you transition to a legitimate pharmaceutical-grade product through a licensed provider, demand third-party HPLC testing and chain-of-custody documentation.

Understand the difference between 503A and 503B. A legitimate 503A pharmacy (licensed by your state) can compound for you if:

1. A valid prescription exists from a licensed prescriber
2. No adequate approved alternative is available
3. The compounding is patient-specific (not bulk manufacturing)

A 503B Outsourcing Facility is FDA-regulated but operates under different rules and cannot dispense directly to patients without going through a licensed pharmacy or healthcare facility.

The Regulatory Trajectory

Expect continued FDA clarification on peptides, especially those with no approved pharmaceutical equivalent. BPC-157, TB-500, AOD-9604, and other research peptides remain in gray zones because no company has commercialized them through FDA approval pathways. This doesn't make them legal—it makes their status uncertain.

Companies like HIMS are choosing to de-risk by exiting the compounding space entirely and focusing on pharmaceutical-grade products they can defend legally.

Bottom Line

The HIMS decision signals that the regulatory environment for compounded semaglutide, and by extension compounded peptides and hormones, is tightening. The gray zone is closing. If you're considering peptide therapy or hormone optimization, obtain baseline labs, work with a provider who prescribes pharmaceutical-grade formulations, and request third-party testing to verify product integrity. The era of low-cost compounded alternatives may be contracting—and that shifts the risk-benefit calculus for users.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.